This shortcoming of PI3K/AKT/mTOR inhibitors as therapeutic targets in melanoma treatment is attributed to feedback loops derived from the inhibition of PI3K/mTOR leading to the activation/reactivation of aberrant signaling pathways like RAS/RAF/MEK/ERK [39,40]. The gene discussed is AKT1; the disease is melanoma.